معرفی
Georges Lacaud is a Professor and Senior Group Leader at the Cancer Research UK Manchester Institute, University of Manchester. His research focuses on understanding the molecular mechanisms underlying blood cell development and leukemia, with particular emphasis on hematopoietic stem cell (HSC) emergence and the role of transcription factors like RUNX1, GFI1, and MOZ in normal and malignant hematopoiesis.
His laboratory has pioneered studies using embryonic stem cell differentiation systems to dissect the endothelial-to-hematopoietic transition (EHT) and developed novel methods for direct reprogramming of fibroblasts into hematopoietic progenitors. Key contributions include discovering the critical role of RUNX1 in regulating endothelial identity during EHT and elucidating MOZ's epigenetic functions in HSC self-renewal and leukemia pathogenesis.
Research interests span regenerative medicine applications, therapeutic strategies for acute myeloid leukemia (AML), and the interplay between developmental pathways and oncogenesis. His work contributes to UN Sustainable Development Goals related to good health and well-being (SDG 3) through advancements in blood cell therapies and cancer treatments.
Collaborations with institutions like the Manchester Regenerative Medicine Network and Christabel Pankhurst Institute highlight his interdisciplinary approach to addressing clinical challenges in hematology and oncology.
